Can 8,000 patient records unlock pancreatic Cancer's hidden patterns?
NCT ID NCT06713525
First seen Sep 01, 2026 · Last updated Sep 04, 2026 · Updated 2 times
Summary
This observational study follows 8,000 people with pancreatic cancer to map their real-world diagnostic and treatment journeys. Researchers will track overall survival and look for factors that influence treatment decisions and outcomes, including patient-reported experiences. The goal is to build a detailed picture of how pancreatic cancer is managed outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal patterns in how pancreatic cancer is diagnosed and treated in everyday practice, potentially guiding better care strategies.
- What could go wrong
- As an observational study, it cannot prove cause and effect. The findings may not apply beyond the Copenhagen population, and data quality depends on real-world records.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 8,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Dec 2036
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients with pancreatic cancer referred to Department of Oncology, Herlev Hospital, Denmark within the study period will be invited to participate.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Histologically confirmed pancreatic cancer Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Oncology
RECRUITINGHerlev, 2730, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill duo outsmart a Hard-to-Treat pancreatic cancer mutation?
- Can a new drug combo outsmart RAS-Mutated pancreatic cancer?
- Can protein patterns in stored tumors point to new treatment targets?
- Can a triple therapy shrink pancreatic tumors enough for complete surgery?
- Personalized drug matching put to the test in pancreatic cancer
- Can a radioactive antibody light up hidden tumors on PET scans?